Clinical trials: Genital Neoplasm
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Cancers, Endometrial Cancer
A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan
Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor.
- Conditions
- Cervical Cancers, Endometrial Cancer, Ovarian Cancer
- Trial name
- HERGYN (NCT06925113)
- Where
- 5 sites in Taiwan
- Volunteers
- 509 people
- Sponsor
- Daiichi Sankyo
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Platinum-resistant Recurrent Ovarian Cancer (PROC)
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single…
- Trial name
- NCT07462468
- Testing
- WSK-IM02
- Volunteers
- 36 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Colorectal Cancer, Ovarian Cancer
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT04503980
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Ovarian Cancer
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region
A prospective, multi-centre, epidemiological observational study designed to evaluate the prevalence of BRCA1 and BRCA2 (BReast CAncer gene) mutations in current and newly diagnosed ovarian cancer patients across different…
- Trial name
- PREDICT (NCT03082976)
- Where
- United Arab Emirates
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00250276
- Testing
- Cervarix™
- Where
- 8 sites in Denmark, Lithuania and 1 more
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Ovarian Cancer
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer.
- Trial name
- NCT04718740
- Testing
- fluzoparib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Prostatic Neoplasms
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients.
- Trial name
- NCT00061035
- Testing
- Transgenic Lymphocyte Immunization Vaccine (TLI)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cosmo Bioscience
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Ovarian Cancer
D9319C00001- 1L OC Mono Global RCT
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high…
- Trial name
- MONO-OLA1 (NCT04884360)
- Testing
- Olaparib
- Where
- 89 sites in Chile, China and 8 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Glioblastoma, Squamous Cell Carcinoma
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.
- Conditions
- Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT05974410
- Testing
- AVM0703, Hydrocortisone, Proton pump inhibitor
- Sponsor
- AVM Biotechnology Inc
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer
- Trial name
- NCT03677960
- Testing
- Topical ABI-1968 cream
- Where
- 2 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Antiva Biosciences
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Psychological Stress, Cardiopulmonary Bypass Surgery
CARINAE for Stress Relief in Perioperative Care
Preventing pre-surgical stress can help patients achieve positive outcomes on health and well-being. However, very few patients receive adequate stress relief support prior to a surgical procedure.
- Conditions
- Psychological Stress, Cardiopulmonary Bypass Surgery, Coronary Artery Bypass Surgery, Cardiac Valve Replacement
- Trial name
- CARINAE (NCT05184725)
- Testing
- SaMD CARINAE
- Where
- 5 sites in Italy, Netherlands and 1 more
- Volunteers
- 50 people
- Sponsor
- Adhera Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.